Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Among the heaviest declines in the SBF 120, Genfit stock threatens its 8.92€ support level

The Lille-based biotech remains under pressure in mid-morning trading and ranks among the weakest performers on the Paris index. The decline extends a very difficult month in a French market that is posting modest losses.


Among the heaviest declines in the SBF 120, Genfit stock threatens its 8.92€ support level

A support level below 8.92€ breached, three days after an initial warning

The Genfit stock is down 2.37% to 9.08€, among the steepest falls in the SBF 120, while the index is down 0.34%. The price is nevertheless holding above the 8.92€ support level, which had wavered on October 5th before holding up during the session. The gap is now only 1.8%, placing this level at the center of trading. The stock is trading 15.3% below its 20-day moving average and 5.2% below its 200-day moving average, a positioning that confirms medium-term deterioration. The RSI at 33 is approaching the oversold zone without entering it.

Over one month, the decline reaches 34.1%, and nearly 32.2% over three months, far from the 165.7% gains over one year. On net short positions, three funds collectively hold 2.06% of the capital according to available declarations, the latest dated October 2nd. This level has increased by 2.06 percentage points in thirty days, indicating selling pressure that has built up over several weeks. This figure remains modest in absolute terms and is insufficient, on its own, to qualify as a movement of generalized loss of confidence.

A slide that began with first-half results on September 28th

The stock had rebounded on September 28th, leading the SBF 120, before the publication of first-half results. Genfit posted cash reserves of 113.8 million euros and Iqirvo royalties tripled to 21 million euros, but a net loss widened to 26.1 million euros compared to 10 million euros a year earlier. The stock declined the next day and has failed to regain momentum since.

The Paris market is evolving in a context of elevated French interest rates: the 10-year OAT stands at 4.72% according to the latest reading on October 6th, 1.27 percentage points above the Bund. The CAC 40 is down 0.38% this Wednesday. The next support level to watch remains 8.92€, which the price is approaching again this morning.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36,4 millions d'euros
  • Quarterly revenue: 36,4 millions d'euros
  • Revenue growth: -7,1 %
Guidance from the release
  • « conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
  • Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
  • Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
  • Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
  • Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
  • Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
  • Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours